Can quantitative surface antigen levels and systemic immune-inflammation index be predictive as a new indicator for the initiation of treatment in chronic hepatitis b?


Koroglu M., Ayvaz M. A., Bakan S. B., Sirin A., AKYÜZ Ü.

European Journal of Gastroenterology and Hepatology, cilt.36, sa.4, ss.489-497, 2024 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 4
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1097/meg.0000000000002737
  • Dergi Adı: European Journal of Gastroenterology and Hepatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.489-497
  • Anahtar Kelimeler: APRI, chronic hepatitis B, FIB-4, surface antigen, systemic immune-inflammation index, systemic inflammatory response index
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objectives The natural history of chronic HBV infection (CHB) is generally divided into four phases: HBeAg-positive chronic HBV infection (EPCI) and -hepatitis (EPCH), HBeAg-negative chronic HBV infection (ENCI) and -hepatitis (ENCH). This study aimed to investigate changes in serum quantitative surface antigen (qHBsAg), systemic immune-inflammation index (SII) and systemic inflammatory response index (SIRI) in a large number of CHB patients. Method Three hundred seventy-two CHB patients who underwent liver biopsy between January 2015 and February 2020 were evaluated. Results The SII-values were strongly significant between EPCI-EPCH (P = 0.002), however, there was significant difference between ENCI-ENCH (P = 0.025). Considering the SIRI results, there was a significant difference between both EPCI-EPCH (P = 0.009) and ENCI-ENCH (P = 0.118). In HBeAg-positive patients HBV-DNA, qHBsAg, and SII were found to be predictive (P = 0.029, P = 0.039, P = 0.027, respectively) while in HBeAg-negative patients, age, AST, HBV-DNA, qHBsAg, SII, and SIRI were found to be predictive (P = 0.047, P = 0.084, P = <0.001, P = 0.001, P = 0.012, P = 0.002, respectively). In EPCH phase, whereby accuracy rate results of HBV-DNA, qHBsAg, and SII were 75.3%, 73.4%, and 60.4%, respectively, while in the ENCH phase the accuracy rates of age, AST, HBV-DNA, qHBsAg, SII, and SIRI values were 57.8%, 65.6%, 68.3%, 63.8%, 57.3% and 53.2%, respectively. Conclusion HBV-DNA, qHBsAg, and SII are predictive in EPCH patients. Age, AST, HBV-DNA, qHBsAg, SII and SIRI are all predictive in ENCH patients. In patients with CHB, we recommend using SII to distinguish between EPCI-EPCH and ENCI-ENCH. Based on its sensitivity and features, we believe that qHBsAg and SII are suitable measuring instruments in discrimination both of EPCI-EPCH and ENCI-ENCH.